ABCELLERA BIOLOGICS INC (ABCL)

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2024.

Which stocks are moving after the closing bell on Monday?

Stay updated with the stocks that are on the move in today's after-hours session.

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript

ABCL earnings call for the period ending June 30, 2024.

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Wall Street analysts say this drug developer can more than double your money.

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

3 Stock Gems Hiding in the Nasdaq

If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2024.

ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024

ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies